Advertisement

Pharmaceutisch Weekblad

, Volume 2, Issue 1, pp 509–523 | Cite as

Klinische farmacologie

Cui bono (oftewel: wat koop je ervoor)?
  • F. W. J. Gribnau
Voordrachten
  • 19 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatuur

  1. Armitage, P. (1975)Sequential medical trials, 2nd Ed. Blackwell, Oxford.Google Scholar
  2. Aznar-Ramos, R., e.a. (1969) Incidence of side effects with contraceptive placebo,Am. J. Obstet. Gynecol. 105, 1144.Google Scholar
  3. Benowitz, N. L., e.a. (1978) Clinical pharmacokinetics of lignocaine,Clin. Pharmacokinetics 3, 177.Google Scholar
  4. Beumer, H. M. (1969) Klinische farmacologie (ingezonden),Ned. Tijdschr. Geneesk. 113, 1515.Google Scholar
  5. Bockhoven, P. N. van, e.a (1977) Geneesmiddelgebruik in vier huisartspraktijken,Huisarts en Wetenschap 20, 111.Google Scholar
  6. Breckenridge, A., e.a. (1978) Postgradutate education in therapeutics: experience in Merseyside,Brit. Med. J. 2, 671.Google Scholar
  7. Breimer, D. D. (1979) Opwinding over Halcion sluit objectiviteit uit,NRC-Handelsblad, 1 augustus.Google Scholar
  8. Brouwers, J. R. B. J., e.a. (1979) Halcion®-verbod: een hazeslaap van zes maanden?Pharm. Weekblad 114, 1272.Google Scholar
  9. Canadian Cooperative Study Group (1978) A randomized trial of aspirin and sulfinpyrazone in threatened stroke,New Engl. J. Med. 299, 53.Google Scholar
  10. Commentary (1979) Laetrile on trial,J. Am. Med. Assoc. 242, 719.Google Scholar
  11. Coombs, R. H. (1978)Mastering Medicine, professional socialization in medical school, Free Press/Macmillan, New York.Google Scholar
  12. Crooks, J., e.a. (1979)Drugs and the elderly; perspectives in geriatric clinical pharmacology, Macmillan, London.Google Scholar
  13. Dettli, J. (1976) Therapeutische Urteilsbildung. In:Klinische Pharmakologie und Pharmakotherapie (Kuemmerle H. P., e.a. Eds.) Urban & Schwarzenberg, München, 9.Google Scholar
  14. Dollery, C. T. (1979) A bleak outlook for placebos (and for science)Eur. J. Clin. Pharmacol 15, 219.Google Scholar
  15. Dunlop, D. (1973)Medicines in our time, The Nuffield Provincial Hospitals Trust.Google Scholar
  16. Dunne, M., e.a. (1973) Indications and warnings about chloramphenicol (Based on a report for the International Organization of Consumers Unions)Lancet II, 781.Google Scholar
  17. Dunning, A. J. (1979) Vasolastine, een Hollands drama,Elseviers Magazine, 27 januari.Google Scholar
  18. Editorial (1973) The pharmacist and his special knowledge,Lancet I, 141.Google Scholar
  19. Editorial (1974) Prescribers' Choice,Lancet II, 705.Google Scholar
  20. Editorial (1978) Freedom to prescribe in ignorance,Brit. Med. J. 1, 1573.Google Scholar
  21. Editorial (1978) Expanding role for pharmacists,Brit. Med. J. 2, 911.Google Scholar
  22. Editorial (1978) On teaching an old drug new tricks,J. Am. Med. Assoc. 240, 2288.Google Scholar
  23. Editorial (1978), WHO on essential drugs,Lancet II, 977.Google Scholar
  24. Editorial (1979) Controlled trials: planned deception?Lancet I, 534.Google Scholar
  25. Editorial (1979) Desert-island drugs,Lancet I, 423.Google Scholar
  26. Editorial (1979) Drugs for the third world — a double standard,Lancet I, 709.Google Scholar
  27. Editorial (1979) The real world of drug prescribing,Lancet II, 781.Google Scholar
  28. Elstein, A. S., e.a. (1978)Medical Problem Solving: an analysis of Clinical Reasoning, Harvard University Press, Cambridge, Mass.Google Scholar
  29. Federatieve Vergadering (1974) Abstracts Mikrosymposium Klinische Farmacologie,Samenvattingenboekje, 94.Google Scholar
  30. Feen, J. A. E. van der (1979)De bestrijding van hypertensie in de huisartspraktijk, Nederlandse Hartstichting, 's-Gravenhage.Google Scholar
  31. Fehr, K., e.a. (1978)International Co-ordination of drug trials, European League against Rheumatism, Basle.Google Scholar
  32. Formularium Nederlandse Apothekers, uitgave voor artsen (1974) 3e druk, KNMP, 's-Gravenhage.Google Scholar
  33. Formularium Nijmegen (1978) Instituut van Samenwerkende Algemene Ziekenfondsen, Nijmegen.Google Scholar
  34. Fost, N. (1979) Consent as a barrier to research,New Engl. J. Med. 300, 1272.Google Scholar
  35. Freiman, J. A. (1978) The importance of beta, the type 11 error and sample size in the design and interpretation of the randomized control trial,New Engl. J. Med. 299, 690.Google Scholar
  36. Gold, H. (1952) The proper study of mankind is man,Am. J. Med. 12, 619.Google Scholar
  37. Good, C. S. (Ed) (1976)The principles and the practice of clinical trials, Churchill Livingstone, Edinburgh.Google Scholar
  38. Gormley, P. E. (1979) Kinetics of cis-dichlorodiammineplatinum,Clin. Pharmacol. Therap. 25, 351.Google Scholar
  39. Gray, B. H. (1975)Human subjects in medical experimentation, Wiley & Sons, New York.Google Scholar
  40. Gross, F. H. (1978) The thorny path of clinical pharmacology,Clin. Pharmacol. Therap. 24, 383.Google Scholar
  41. Gross, F. H., e.a. (1977)Drug Monitoring, Academic Press, New York.Google Scholar
  42. Gumpel, J. M. (1978) Personal Therapeutics: rheumatoid arthritis,Brit. Med. J. 2, 1068.Google Scholar
  43. Hage-Noël, G. L. M. A. (1978) Apotheker en gezondheidszorg in ontwikkelingslanden,Pharm. Weekblad 113, 1161.Google Scholar
  44. Herxheimer, A. (1976) Assessing untoward effects. In:Chemotherapy; Vol. 4,Pharmacology of Antibiotics (J. D. Williams, e.a., Eds.) Plenum Press, New York, 287.Google Scholar
  45. Herxheimer, A. (1976) Towards parity for therapeutics in clinical teaching,Lancet II, 1186;Ibidem (1976) Sharing the responsibility for treatment: how can the doctor help the patient?Lancet II, 1294.Google Scholar
  46. Herxheimer, A., e.a. (1978) Minimum information needed by prescribers,Brit. Med. J. 2, 1129.Google Scholar
  47. Hoofdredactioneel (1979) Laetrile nu ook in de Nederlandse rechtzaal,Ned. Tijdschr. Geneesk. 123, 1159.Google Scholar
  48. Hoofdredactioneel (1979) Halcion — ontmaskering van een mythe,Ned. Tijdschr. Geneesk. 123, 1653.Google Scholar
  49. Ivey, K. J. (1975) Are anticholinergics of use in the irritable colon syndrome?Gastroenterology 68, 1300.Google Scholar
  50. Johnson, F. N., e.a. (1977)Clinical trials, Blackwell, Oxford.Google Scholar
  51. Jongkees, L. B. W. (1979) Alternatieve kankertherapie,Ned. Tijdschr. Geneesk. 123, 1071.Google Scholar
  52. Kalsbeek, F., e.a. (1978)Materia medica selecta: praktische handleiding voor het rationeel kiezen en voorschrijven van geneesmiddelen, 2e druk, Elsevier, Amsterdam.Google Scholar
  53. Kelton, J. G., e.a. (1978) Thrombogenic effect of highdose aspirin in rabbits,J. Clin. Invest. 62, 892.Google Scholar
  54. Khandekar, J. D., e.a. (1979) Studies of amygdalin toxicity in rodents,J. Am. Med. Assoc. 242, 169.Google Scholar
  55. Kleijn, E. van der, e.a. (Eds.) (1977)Clinical Pharmacy, Elsevier/North-Holland Biomedical, Amsterdam.Google Scholar
  56. Koninklijke Nederlandse Akademie van Wetenschappen (1979) Brief aan Minister-President, d.d. 31 mei 1979,Pharm. Weekblad 114, 738.Google Scholar
  57. Koperberg, I. P. L. (1978) Publiciteit voor een slaapmiddel in de lekepers,Ned. Tijdschr. Geneesk. 122, 1677.Google Scholar
  58. Krantz, J. C. (1974)Historical Medical Classics involving New Drugs, Williams & Wilkins, Baltimore.Google Scholar
  59. Kroef, C. van der (1979) Halcion, een onschuldig slaapmiddel?Ned. Tijdschr. Geneesk. 123, 1160.Google Scholar
  60. Lasagna, L. (Ed) (1976)Patient Compliance, Futura, Mount Kisco N. Y.Google Scholar
  61. Lasagna, L. (1979) Placebos and controlled trials under attack,Eur. J. Clin. Pharmacol. 15, 373.Google Scholar
  62. Loewi, O. (1910) Pharmakologie und Klinik,Wien. Klin. Woch. schr. 23, 273.Google Scholar
  63. Lucchelli, P. E., e.a. (Eds.) (1976)Rationality of drug development, Excerpta Medica, Amsterdam.Google Scholar
  64. MacLeod, S. M., e.a. (1979) Pharmacology teaching at the University of Toronto: a survey of students and graduates,Clin. Pharmacol. Therap. 25, 236 (abstract).Google Scholar
  65. McNulty, H., e.a. (1979) Drug names that look or sound alike,Brit. Med. J. 2, 836.Google Scholar
  66. Merkus, F. W. H. M. (1974)De kwaliteit van de huidige farmacotherapie (inaugurele rede, Universiteit van Amsterdam) Erven Bohn, Amsterdam.Google Scholar
  67. Merkus, F. W. H. M. (1978) Farmaceutische, medische en therapeutische aspecten van therapietrouw,Pharm. Weekblad 113, 141.Google Scholar
  68. Merkus, F. W. H. M. (1979) Persoonlijke mededeling.Google Scholar
  69. Meyer, P. B. (1976)Drug experiments on prisoners, Heath & Cy. Lexington, Mass.Google Scholar
  70. Monson, R. A. (1978) The accuracy of the medical record as an index of outpatient drug therapy,J. Am. Med. Assoc. 240, 2182.Google Scholar
  71. Nefarma Brochure:Zelfmedicatie in de gezondheidszorg, Nefarma, Utrecht.Google Scholar
  72. Norris, R. M., e.a. (1978) Protective effect of propranolol in threatened myocardial infarction,Lancet II, 907.Google Scholar
  73. Offerhaus, L. (1978) Tweehonderd essentiële geneesmiddelen,Ned. Tijdschr. Geneesk. 122, 944.Google Scholar
  74. Ogilvie, R. I. (1978) Clinical pharmacokinetics of theophylline,Clin. Pharmacokinetics 3, 267.Google Scholar
  75. Penn, R. G. (1979) The state control of medicines: the first 3000 years,Brit. J. Clin. Pharmacol. 8, 293.Google Scholar
  76. Praktijk-Perikel (1979) Kuren,Medisch Contact 34, 1362.Google Scholar
  77. Regeling en Klapper (1977) Medisch Farmaceutische Voorlichting over het voorschrijven van geneesmiddelen voor rekening van de ziekenfondsverzekering, Centrale Medisch-Pharmaceutische Commissie van de Ziekenfondsraad, Amstelveen.Google Scholar
  78. Reinfarction Trial Research Group (1978) Sulfinpyrazone in the prevention of cardiac death after myocardial infarction,New Engl. J. Med. 298, 289.Google Scholar
  79. Relman, A. S. (1979) The sulindac story: what is medical news?New Engl. J. Med. 300, 733.Google Scholar
  80. Relman, A. S. (1979) Who reviews the ads?New Engl. J. Med. 301, 999.Google Scholar
  81. Richards, R. K. (1978)Continuing Medical Education, Yale University Press, New Haven.Google Scholar
  82. Roth, H. P., e.a. (Eds.) (1979) National conference on clinical trials methodology,Clin. Pharmacol. Therap. 25/5, part 2, 629–766.Google Scholar
  83. Royal College of General Practitioners (1974)Oral contraceptives & health (interim report) Pitman Medical, London.Google Scholar
  84. Sackett, D. L., e.a (Eds.) (1976)Compliance with therapeutic regimens, Johns Hopkins University Press, Baltimore.Google Scholar
  85. Silverman, M., e.a. (1974)Pills, profits and politics, University of California Press, Berkeley.Google Scholar
  86. Silverman, M. (1976)The Drugging of the Americas, University of California Press, Berkeley.Google Scholar
  87. Smith, W. Mc. F. (1978) Drug choice in disease states. In:Clinical Pharmacology: basic principles in therapeutics, 2nd Edition (Melmon, K. L., e.a., Eds.) Macmillan, New York, 3.Google Scholar
  88. Sorgedrager, Y., e.a. (1974) Beoordeling van klinisch geneesmiddelenonderzoek,Ned. Tijdschr. Geneesk. 118, 1300.Google Scholar
  89. Stewart, R. B., e.a. (Eds.) (1977)Drug monitoring: a requirement for responsible drug use, Williams and Wilkins, Baltimore.Google Scholar
  90. Stoter, G., e.a. (1979) Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastin and bleomycin in advanced testicular non-seminoma,Lancet I, 941.Google Scholar
  91. The Sunday Times Insight Team (1979)Suffer the Children: The Story of Thalidomide, Adré Deutsch, London.Google Scholar
  92. Turner, P. (1979) The Royal Commission: a clinical pharmacologist's view,Lancet II, 735.Google Scholar
  93. Tyrer, P. (1974) The benzodiazepine Bonanza,Brit. Med. J. 3, 709.Google Scholar
  94. Voorlichting Prijzen Geneesmiddelen (1979) Commissie Voorlichting Prijzen Geneesmiddelen, Velp (Gld).Google Scholar
  95. Wade, O. L. (1970) The monitoring of adverse reactions to drugs and the discipline of therapeutic auditing. In:de Schaepdryver, A. F. (Ed.) Proceed of the International Symposium on Clinical Pharmacology.Arch. Intern. Pharmacodyn. 155.Google Scholar
  96. Walker, C. A., e.a. (Eds.) (1977)Practical clinical pharmacy, Stratton Intercontinental, New York.Google Scholar
  97. WHO (1970) Clinical Pharmacology: Scope, organization, training,Tech. Rep. Ser. No. 446.Google Scholar
  98. WHO (1975) Guidelines for evaluation of drugs for use in man,Tech. Rep. Ser. No. 563.Google Scholar
  99. WHO (1977) The selection of essential drugs,Tech. Rep. Ser. No. 615.Google Scholar
  100. WHO (1979) Studies in drug utilisation.Publ. Eur. Ser. Reg. No. 8, Copenhagen.Google Scholar
  101. Williams, C. J., e.a. (1979) Cis-platinum: a new anticancer agent,Brit. Med. J. 1, 1689.Google Scholar
  102. Willkens, R. F. (1978) The use of nonsteroidal anti-inflammatory agents.J. Am. Med. Assoc. 240, 1632.Google Scholar
  103. Wright, H. J., e.a. (1979)Clinical Thinking and Practice: diagnosis and decision in patient care, Churchill Livingstone, Edinburgh.Google Scholar
  104. Wright, V., e.a. (1979) What shall we teach undergraduates?Brit. Med. J. 1, 805.Google Scholar
  105. Zelen, M. (1979) A new design for randomized clinical trials,New Engl. J. Med. 300, 1242.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1980

Authors and Affiliations

  • F. W. J. Gribnau
    • 1
  1. 1.Kliniek voor Inwendige ZiektenSt. RadboudziekenhuisHB Nijmegen

Personalised recommendations